IL260965B - The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures - Google Patents

The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures

Info

Publication number
IL260965B
IL260965B IL260965A IL26096518A IL260965B IL 260965 B IL260965 B IL 260965B IL 260965 A IL260965 A IL 260965A IL 26096518 A IL26096518 A IL 26096518A IL 260965 B IL260965 B IL 260965B
Authority
IL
Israel
Prior art keywords
crystalline forms
maleate salt
preparation methods
tlr7 agonist
maleate
Prior art date
Application number
IL260965A
Other languages
English (en)
Hebrew (he)
Inventor
Zhaozhong Ding
Fei Sun
Ling Yang
Yinghu Hu
Yilong Zhou
Zheng Wang
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Zhaozhong Ding
Fei Sun
Ling Yang
Yinghu Hu
Yilong Zhou
Zheng Wang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Zhaozhong Ding, Fei Sun, Ling Yang, Yinghu Hu, Yilong Zhou, Zheng Wang filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of IL260965B publication Critical patent/IL260965B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL260965A 2016-02-05 2018-08-02 The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures IL260965B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610082030.0A CN107043380A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
PCT/CN2017/072890 WO2017133683A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e及其制备方法和用途

Publications (1)

Publication Number Publication Date
IL260965B true IL260965B (en) 2022-02-01

Family

ID=59500111

Family Applications (1)

Application Number Title Priority Date Filing Date
IL260965A IL260965B (en) 2016-02-05 2018-08-02 The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures

Country Status (23)

Country Link
US (2) US10780091B2 (2)
EP (1) EP3412671B1 (2)
JP (1) JP6898336B2 (2)
KR (1) KR102393279B1 (2)
CN (2) CN107043380A (2)
AR (1) AR107547A1 (2)
AU (1) AU2017215800B2 (2)
CA (1) CA3013682C (2)
CL (1) CL2018002089A1 (2)
DK (1) DK3412671T3 (2)
EA (1) EA038794B1 (2)
ES (1) ES2834303T3 (2)
HU (1) HUE052211T2 (2)
IL (1) IL260965B (2)
MX (1) MX374295B (2)
MY (1) MY196762A (2)
NZ (1) NZ745231A (2)
PH (1) PH12018501644B1 (2)
SG (1) SG11201806682TA (2)
TW (1) TWI778951B (2)
UA (1) UA123781C2 (2)
WO (1) WO2017133683A1 (2)
ZA (1) ZA201805185B (2)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
AU2019272478B2 (en) * 2018-05-25 2024-06-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. TLR7 agonist and pharmaceutical combination thereof for treating lung cancer
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
JP7690221B2 (ja) 2020-08-04 2025-06-10 プロジェニア インコーポレイテッド 動力学的に作用するアジュバントアンサンブル
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
ES2232871T3 (es) 1996-07-03 2005-06-01 Sumitomo Pharmaceuticals Company, Limited Nuevos derivados de purina.
DE69817393T2 (de) 1997-11-28 2004-06-17 Sumitomo Pharmaceuticals Co., Ltd. Neue heterozyklische verbindungen
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
WO2012106522A2 (en) 2011-02-04 2012-08-09 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
EP2800569B1 (en) 2012-01-05 2018-07-25 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
DK2906563T3 (en) 2012-10-10 2018-06-06 Janssen Sciences Ireland Uc PYRROLO [3,2-D] PYRIMIDINE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND OTHER DISEASES
AU2013348217B2 (en) * 2012-11-20 2016-10-06 Glaxosmithkline Llc Novel compounds
BR112015011439A2 (pt) 2012-11-20 2017-07-11 Glaxosmithkline Llc composto, composição farmacêutica, composição de vacina, e, uso de um composto
EA028480B1 (ru) 2012-11-20 2017-11-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Новые соединения
KR20160124157A (ko) 2014-02-20 2016-10-26 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 인간 인터페론의 유도인자로서의 피롤로[3,2]피리미딘 유도체
ES2908150T3 (es) 2014-05-01 2022-04-27 Novartis Ag Compuestos y composiciones como agonistas del receptor de tipo Toll 7
PL3137470T3 (pl) * 2014-05-01 2021-10-11 Novartis Ag Związki i kompozycje jako agonisty receptora toll-like 7
HRP20210927T1 (hr) * 2014-08-15 2021-09-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Spojevi pirolopirimidina koje se koriste kao agonist tlr7
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105732635A (zh) 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂
MX2018005388A (es) 2015-11-05 2018-08-16 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatogenos.
UA121345C2 (uk) 2015-11-05 2020-05-12 Чіа Тай Тяньцин Фармасьютікал Груп Ко., Лтд. 7-(тіазол-5-іл)піролопіримідин як агоніст рецептора tlr7
TWI714661B (zh) 2015-11-05 2021-01-01 法商賽諾菲公司 新穎念珠藻素化合物及接合物、其製備與其治療用途
CN107043380A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途
CN107043377A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体

Also Published As

Publication number Publication date
HK1259175A1 (zh) 2019-11-29
AU2017215800B2 (en) 2020-08-20
CA3013682A1 (en) 2017-08-10
UA123781C2 (uk) 2021-06-02
AU2017215800A1 (en) 2018-08-30
ZA201805185B (en) 2024-08-28
NZ745231A (en) 2022-07-29
SG11201806682TA (en) 2018-09-27
EP3412671A1 (en) 2018-12-12
MX2018009500A (es) 2018-12-11
JP2019505532A (ja) 2019-02-28
CA3013682C (en) 2022-06-21
US20200368241A1 (en) 2020-11-26
ES2834303T3 (es) 2021-06-17
US10780091B2 (en) 2020-09-22
CL2018002089A1 (es) 2018-12-07
PH12018501644A1 (en) 2019-06-03
CN108602830A (zh) 2018-09-28
JP6898336B2 (ja) 2021-07-07
TWI778951B (zh) 2022-10-01
EA038794B1 (ru) 2021-10-20
DK3412671T3 (da) 2020-11-09
MY196762A (en) 2023-05-03
MX374295B (es) 2025-03-06
EA201891770A1 (ru) 2019-01-31
US20190070179A1 (en) 2019-03-07
PH12018501644B1 (en) 2022-09-07
BR112018015881A2 (pt) 2018-12-26
AR107547A1 (es) 2018-05-09
CN107043380A (zh) 2017-08-15
KR20180104116A (ko) 2018-09-19
HUE052211T2 (hu) 2021-04-28
KR102393279B1 (ko) 2022-05-02
TW201728588A (zh) 2017-08-16
WO2017133683A1 (zh) 2017-08-10
CN108602830B (zh) 2020-07-28
EP3412671A4 (en) 2019-07-24
EP3412671B1 (en) 2020-09-16

Similar Documents

Publication Publication Date Title
IL260965B (en) The malate salt as an agonist of tlr7, its c, d and e crystal structures, preparation methods and uses of the malate salt and the crystal structures
IL260981B (en) The trifluoroacetate salt of the tlr7 agonist type b crystal structure, preparation, and methods of use
CA3290585A1 (en) Berberine-ursodeoxycholic salt, method of preparation and application therof
IL265730A (en) Crystalline forms and salts of ppar agonist compounds
IL260968B (en) Type a crystal structure of trl7 agonist, methods of preparation and its uses
SMT202500228T1 (it) Forme cristalline di ozanimod e ozanimod cloridrato, e processi per la loro preparazione
IL253360A0 (en) New crystalline forms of neratinib malate and a process for their preparation
PT3580219T (pt) Processo para a preparação de remimazolam e formas de estado sólido de sais de remimazolam
PL3428159T3 (pl) Postacie krystaliczne soli mesylanowej pochodnej pirydynyloaminopirymidyny, sposoby ich wytwarzania i ich zastosowania
IL253204A0 (en) Trifluoroacethydrazide compound, method for its preparation and use for preparing a medical preparation
ZA201704743B (en) Mangiferin-6-o-berberine salt and preparation method and use thereof
EP3677575A4 (en) CRYSTALLINE FORM OF OZANIMODHYDROCHLORIDE AND PRODUCTION METHOD THEREFOR
EP3530650A4 (en) CRYSTALLINE FORM OF (R) -4-HYDROXY-2-OXO-1-PYRROLIDINE ACETAMIDE, PRODUCTION METHOD THEREFOR, AND USE THEREOF
EP3327012A4 (en) Crystalline forms of bilastine and preparation methods thereof
EP3302099A4 (en) Enhanced salt compositions and methods of preparation thereof
EP3277098A4 (en) Novel and useful edible salt and methods of use and production thereof
EP3216791A4 (en) Polymorphic substance of yonkenafil hydrochloride, preparation method therefor, and composition and use thereof
ME03727B (me) Zamjena za so i njena primena
IL246835A0 (en) Improved process for the preparation of trazodone and its hydrochloride salt
HUE059444T2 (hu) Morfolinszármazék sója és ennek kristályformája, valamint ezek elõállítási eljárása, gyógyszerkészítménye és alkalmazása
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
SG11201708692WA (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof
EP3110459A4 (en) Biocidal composition, preparation and methods of use thereof
GB2554842B (en) Novel crystalline form of imazapyr, its preparation and use